Midazolam (Versed)

Subscribe to Selected New Research on Midazolam

1815 relevant articles (194 outcomes, 248 trials/studies) found for this Drug

Description: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.

Also Known As:

Versed; Dormicum; Midazolam Hydrochloride; Midazolam Maleate; Ro 21-3981; Hydrochloride, Midazolam; Maleate, Midazolam; Ro 21 3981; Ro 213981; 4H-Imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 25

2-Ring Heterocyclic Compounds

Benzazepines: 2

Benzodiazepines: 4233

Midazolam: 1815

1-hydroxymethylmidazolam: 6

climazolam: 2

1-hydroxymethylmidazolam glucuronide

4-hydroxymidazolam

6-(2-chlorophenyl)-4-hydroxy-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxamide

8-chloro-6-(2-chlorophenyl)-4H-imidazo(1,5-a)(1,4)-benzodiazepine-3-carboxamide

Experts

1.	Hirshman, Elliot: 6 articles (07/2006 - 01/2003)
2.	Yamanouchi, Hideo: 3 articles (10/2007 - 01/2006)
3.	Danhof, Meindert: 3 articles (07/2007 - 02/2004)
4.	Sugai, Kenji: 3 articles (06/2007 - 01/2002)
5.	Fisher, Julia: 3 articles (03/2006 - 12/2003)
6.	Arndt, Jason: 3 articles (03/2006 - 12/2003)
7.	Henthorn, Thomas: 3 articles (03/2006 - 12/2003)
8.	Passannante, Anthony: 3 articles (03/2006 - 12/2003)
9.	Goldman, M: 3 articles (03/2003 - 01/2000)
10.	Lahat, E: 3 articles (03/2003 - 01/2000)

Related Diseases

1.	Seizures (Seizure) 12/01/1997 - "There are limited studies that midazolam can be used successfully to treat seizures in adults and children. " 11/01/1999 - "Since rapid seizure control minimizes the chance of brain damage, use of midazolam as an anticonvulsant may lead to improved clinical outcome in the treatment of nerve agent seizures." 06/01/2003 - "The present study was designated to examine the efficacy of buccal midazolam in children at different ages with seizures of more than 5 min duration. " 09/25/2001 - "OBJECTIVE:- To evaluate the efficacy of continuous intravenous midazolam (cIV-MDZ) for attaining sustained seizure control in patients with RSE. " 01/01/2006 - "Buccal midazolam is effective for acute treatment of seizures." Order ALL the reference details at left...
2.	Pain (Aches) 02/01/1993 - "Midazolam causes less pain on injection, a significantly greater degree of early sedation, and a more rapid return to baseline function." 11/01/2008 - "N(2)O was more effective in reducing pain compared with midazolam as measured using the Face, Legs, Activity, Cry, Consolability (FLACC) scale (p=0.010), parental estimate of pain (p=0.009), and nursing estimate of pain (p=0.007). " 04/01/1994 - "Midazolam 1 mg was effective in the males (from 45% to 10%) and tended to allay patients' pain feeling in the females (from 40% to 23%). " 11/01/1991 - "In these two cases, the addition of midazolam appeared to be effective in controlling intractable neoplastic pain." 01/01/2009 - "There are many methods for pain relief and to treat discomfort during the procedure but we compared the efficacy of intravenous (IV) midazolam for pain control. " Order ALL the reference details at left...
3.	Status Epilepticus (Complex Partial Status Epilepticus) 12/01/2006 - "OBJECTIVE: To assess the efficacy of high-dose midazolam in the treatment of refractory status epilepticus in children. " 03/01/2003 - "[Proposal to obtain a licensed application for midazolam (Dormicam) as a drug effective for status epilepticus]" 09/01/1999 - "CONCLUSION: Midazolam infusion, as per our described algorithm, is effective in terminating refractory status epilepticus. " 07/01/1998 - "In conclusion, midazolam infusion is an effective and safe therapeutic approach for the management of childhood status epilepticus." 05/01/1997 - "Midazolam infusion is thus an effective and safe therapeutic approach for the management of childhood status epilepticus." Order ALL the reference details at left...
4.	Amnesia (Dissociative Amnesia) 02/01/2005 - "A significantly greater number of patients in the midazolam group graded overall tolerance as "excellent or good" (70.8% vs. 49.2%, p = 0.012) and reported a partial to complete amnesia response (52.3% vs. 32.3%, p = 0.02) when compared with the control group. " 02/22/1992 - "There was significant amnesia for material presented after drug administration, as well as for dental events and this was significantly greater for midazolam. " 01/01/1990 - "Amnesia for the immediate postoperative period was significantly greater after midazolam (P = 0.0001)." 05/01/1989 - "Midazolam produced significantly greater amnesia both at the time of induction and 30 minutes postoperatively. " 04/01/1985 - "Both drugs provided good-quality sedation, with midazolam producing a significantly greater degree of amnesia. " Order ALL the reference details at left...
5.	Postoperative Nausea and Vomiting (PONV) 07/01/2009 - "RESULTS: Patients in the midazolam group reported a lower incidence of total PONV, and a lower frequency of rescue antiemetic request than those in the placebo group (p < 0.05). " 02/01/2009 - "Low dose intravenous midazolam for prevention of PONV, in lower abdominal surgery--preoperative vs intraoperative administration." 05/01/2006 - "Intrathecal midazolam, 1 mg and 2 mg, decreased postoperative nausea and vomiting." 01/01/2005 - "A continuous low dose IV midazolam infusion was added to his treatment regimen (as is instituted for recalcitrant postoperative nausea and vomiting) with benefit, but not total symptom resolution. " 05/01/2004 - "Similarly, fewer patients in the midazolam group experienced postoperative vomiting than placebo group patients (8%vs. 21%), although this difference did not reach statistical significance. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Diazepam (Valium)
2.	Ketamine
3.	Propofol (Diprivan)
4.	Benzodiazepines
5.	Fentanyl (Sublimaze)
6.	Lorazepam (Ativan)
7.	Flumazenil (Romazicon)
8.	Morphine (MS Contin)
9.	Bupivacaine (Bupivacaine Hydrochloride)
10.	Lidocaine (Xylocaine)

Related Therapies and Procedures

1.	Premedication
2.	Analgesia
3.	Anesthesia
4.	Spinal Anesthesia
5.	Artificial Respiration (Mechanical Ventilation)

Best Treatments:
Research Summary Report
on Seizures

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2227 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>